 | • レポートコード：MRC2012A4640 • 出版社/出版日：GlobalInfoResearch / 2020年12月21日 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、100ページ • 納品方法：Eメール（納期：2~3日） • 産業分類：医薬品、医療 |
| Single User | ￥515,040 (USD3,480) | ▷ お問い合わせ |
| Multi User | ￥772,560 (USD5,220) | ▷ お問い合わせ |
| Corporate User | ￥1,030,080 (USD6,960) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 本調査レポートでは、院内肺炎（HAP）治療薬の世界市場を広く調査・分析し、今後の市場展望をまとめております。院内肺炎（HAP）治療薬の種類別市場規模（抗菌、抗ウイルス、抗真菌）、用途別市場規模（病院、診療所、その他）、地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、中国、日本、東南アジア、南米、中東、アフリカなど）、市場動向、メーカー別販売量と市場シェア、販売チャネルなどの情報を掲載しています。 ・市場概要 ・メーカー情報（販売量、市場シェア、製品概要、SWOT分析）：Pfizer、Arsanis、Mylan、GlaxoSmithKline、AstraZeneca、Merck、Shinogi、Teva Pharmaceutical Industries、Novartis、Combioxin、Sun Pharmaceutical Industries、The Medicines Company、Theravance Biopharma、 ・地域別グローバル市場分析 2015年-2020年 ・院内肺炎（HAP）治療薬の北米市場（アメリカ、カナダ、メキシコ） ・院内肺炎（HAP）治療薬のヨーロッパ市場（ドイツ、イギリス、フランス、ロシア、イタリア） ・院内肺炎（HAP）治療薬のアジア市場（中国、日本、韓国、インド、東南アジア、オーストラリア） ・院内肺炎（HAP）治療薬の南米市場（ブラジル、アルゼンチン） ・院内肺炎（HAP）治療薬の中東・アフリカ市場（サウジアラビア、トルコ、エジプト、南アフリカ） ・種類別分析：抗菌、抗ウイルス、抗真菌 ・用途別分析：病院、診療所、その他 ・地域別市場規模予測 2021年-2025年 ・販売チャネル、流通業者、代理店 ・調査の結果・結論 |
Market Overview
The global Hospital-acquired Pneumonia (HAP) Drugs market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of xx% in the forecast period of 2020 to 2025 and will expected to reach USD xx million by 2025, from USD xx million in 2019.
The Hospital-acquired Pneumonia (HAP) Drugs market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
Market segmentation
Hospital-acquired Pneumonia (HAP) Drugs market is split by Type and by Application. For the period 2015-2025, the growth among segments provide accurate calculations and forecasts for sales by Type and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
By Type, Hospital-acquired Pneumonia (HAP) Drugs market has been segmented into
Antibacterial
Antiviral
Antifungal
By Application, Hospital-acquired Pneumonia (HAP) Drugs has been segmented into:
Hospitals
Clinics
Other
Regions and Countries Level Analysis
Regional analysis is another highly comprehensive part of the research and analysis study of the global Hospital-acquired Pneumonia (HAP) Drugs market presented in the report. This section sheds light on the sales growth of different regional and country-level Hospital-acquired Pneumonia (HAP) Drugs markets. For the historical and forecast period 2015 to 2025, it provides detailed and accurate country-wise volume analysis and region-wise market size analysis of the global Hospital-acquired Pneumonia (HAP) Drugs market.
The report offers in-depth assessment of the growth and other aspects of the Hospital-acquired Pneumonia (HAP) Drugs market in important countries (regions), including:
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
South America (Brazil, Argentina, etc.)
Middle East & Africa (Saudi Arabia, Egypt, Nigeria and South Africa)
Competitive Landscape and Hospital-acquired Pneumonia (HAP) Drugs Market Share Analysis
Hospital-acquired Pneumonia (HAP) Drugs competitive landscape provides details by vendors, including company overview, company total revenue (financials), market potential, global presence, Hospital-acquired Pneumonia (HAP) Drugs sales and revenue generated, market share, price, production sites and facilities, SWOT analysis, product launch. For the period 2015-2020, this study provides the Hospital-acquired Pneumonia (HAP) Drugs sales, revenue and market share for each player covered in this report.
The major players covered in Hospital-acquired Pneumonia (HAP) Drugs are:
Pfizer
Arsanis
Mylan
GlaxoSmithKline
AstraZeneca
Merck
Shinogi
Teva Pharmaceutical Industries
Novartis
Combioxin
Sun Pharmaceutical Industries
The Medicines Company
Theravance Biopharma
Among other players domestic and global, Hospital-acquired Pneumonia (HAP) Drugs market share data is available for global, North America, Europe, Asia-Pacific, Middle East and Africa and South America separately. Global Info Research analysts understand competitive strengths and provide competitive analysis for each competitor separately.
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Hospital-acquired Pneumonia (HAP) Drugs product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top manufacturers of Hospital-acquired Pneumonia (HAP) Drugs, with price, sales, revenue and global market share of Hospital-acquired Pneumonia (HAP) Drugs in 2018 and 2019.
Chapter 3, the Hospital-acquired Pneumonia (HAP) Drugs competitive situation, sales, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Hospital-acquired Pneumonia (HAP) Drugs breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2015 to 2020.
Chapter 5, 6, 7, 8 and 9, to break the sales data at the country level, with sales, revenue and market share for key countries in the world, from 2015 to 2020.
Chapter 10 and 11, to segment the sales by type and application, with sales market share and growth rate by type, application, from 2015 to 2020.
Chapter 12, Hospital-acquired Pneumonia (HAP) Drugs market forecast, by regions, type and application, with sales and revenue, from 2020 to 2025.
Chapter 13, 14 and 15, to describe Hospital-acquired Pneumonia (HAP) Drugs sales channel, distributors, customers, research findings and conclusion, appendix and data source.
Table of Contents
1 Market Overview
1.1 Hospital-acquired Pneumonia (HAP) Drugs Introduction
1.2 Market Analysis by Type
1.2.1 Overview: Global Hospital-acquired Pneumonia (HAP) Drugs Revenue by Type: 2015 VS 2019 VS 2025
1.2.2 Antibacterial
1.2.3 Antiviral
1.2.4 Antifungal
1.3 Market Analysis by Application
1.3.1 Overview: Global Hospital-acquired Pneumonia (HAP) Drugs Revenue by Application: 2015 VS 2019 VS 2025
1.3.2 Hospitals
1.3.3 Clinics
1.3.4 Other
1.4 Overview of Global Hospital-acquired Pneumonia (HAP) Drugs Market
1.4.1 Global Hospital-acquired Pneumonia (HAP) Drugs Market Status and Outlook (2015-2025)
1.4.2 North America (United States, Canada and Mexico)
1.4.3 Europe (Germany, France, United Kingdom, Russia and Italy)
1.4.4 Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
1.4.5 South America, Middle East & Africa
1.5 Market Dynamics
1.5.1 Market Opportunities
1.5.2 Market Risk
1.5.3 Market Driving Force
2 Manufacturers Profiles
2.1 Pfizer
2.1.1 Pfizer Details
2.1.2 Pfizer Major Business and Total Revenue (Financial Highlights) Analysis
2.1.3 Pfizer SWOT Analysis
2.1.4 Pfizer Product and Services
2.1.5 Pfizer Hospital-acquired Pneumonia (HAP) Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.2 Arsanis
2.2.1 Arsanis Details
2.2.2 Arsanis Major Business and Total Revenue (Financial Highlights) Analysis
2.2.3 Arsanis SWOT Analysis
2.2.4 Arsanis Product and Services
2.2.5 Arsanis Hospital-acquired Pneumonia (HAP) Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.3 Mylan
2.3.1 Mylan Details
2.3.2 Mylan Major Business and Total Revenue (Financial Highlights) Analysis
2.3.3 Mylan SWOT Analysis
2.3.4 Mylan Product and Services
2.3.5 Mylan Hospital-acquired Pneumonia (HAP) Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.4 GlaxoSmithKline
2.4.1 GlaxoSmithKline Details
2.4.2 GlaxoSmithKline Major Business and Total Revenue (Financial Highlights) Analysis
2.4.3 GlaxoSmithKline SWOT Analysis
2.4.4 GlaxoSmithKline Product and Services
2.4.5 GlaxoSmithKline Hospital-acquired Pneumonia (HAP) Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.5 AstraZeneca
2.5.1 AstraZeneca Details
2.5.2 AstraZeneca Major Business and Total Revenue (Financial Highlights) Analysis
2.5.3 AstraZeneca SWOT Analysis
2.5.4 AstraZeneca Product and Services
2.5.5 AstraZeneca Hospital-acquired Pneumonia (HAP) Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.6 Merck
2.6.1 Merck Details
2.6.2 Merck Major Business and Total Revenue (Financial Highlights) Analysis
2.6.3 Merck SWOT Analysis
2.6.4 Merck Product and Services
2.6.5 Merck Hospital-acquired Pneumonia (HAP) Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.7 Shinogi
2.7.1 Shinogi Details
2.7.2 Shinogi Major Business and Total Revenue (Financial Highlights) Analysis
2.7.3 Shinogi SWOT Analysis
2.7.4 Shinogi Product and Services
2.7.5 Shinogi Hospital-acquired Pneumonia (HAP) Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.8 Teva Pharmaceutical Industries
2.8.1 Teva Pharmaceutical Industries Details
2.8.2 Teva Pharmaceutical Industries Major Business and Total Revenue (Financial Highlights) Analysis
2.8.3 Teva Pharmaceutical Industries SWOT Analysis
2.8.4 Teva Pharmaceutical Industries Product and Services
2.8.5 Teva Pharmaceutical Industries Hospital-acquired Pneumonia (HAP) Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.9 Novartis
2.9.1 Novartis Details
2.9.2 Novartis Major Business and Total Revenue (Financial Highlights) Analysis
2.9.3 Novartis SWOT Analysis
2.9.4 Novartis Product and Services
2.9.5 Novartis Hospital-acquired Pneumonia (HAP) Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.10 Combioxin
2.10.1 Combioxin Details
2.10.2 Combioxin Major Business and Total Revenue (Financial Highlights) Analysis
2.10.3 Combioxin SWOT Analysis
2.10.4 Combioxin Product and Services
2.10.5 Combioxin Hospital-acquired Pneumonia (HAP) Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.11 Sun Pharmaceutical Industries
2.11.1 Sun Pharmaceutical Industries Details
2.11.2 Sun Pharmaceutical Industries Major Business and Total Revenue (Financial Highlights) Analysis
2.11.3 Sun Pharmaceutical Industries SWOT Analysis
2.11.4 Sun Pharmaceutical Industries Product and Services
2.11.5 Sun Pharmaceutical Industries Hospital-acquired Pneumonia (HAP) Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.12 The Medicines Company
2.12.1 The Medicines Company Details
2.12.2 The Medicines Company Major Business and Total Revenue (Financial Highlights) Analysis
2.12.3 The Medicines Company SWOT Analysis
2.12.4 The Medicines Company Product and Services
2.12.5 The Medicines Company Hospital-acquired Pneumonia (HAP) Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.13 Theravance Biopharma
2.13.1 Theravance Biopharma Details
2.13.2 Theravance Biopharma Major Business and Total Revenue (Financial Highlights) Analysis
2.13.3 Theravance Biopharma SWOT Analysis
2.13.4 Theravance Biopharma Product and Services
2.13.5 Theravance Biopharma Hospital-acquired Pneumonia (HAP) Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
3 Sales, Revenue and Market Share by Manufacturer
3.1 Global Hospital-acquired Pneumonia (HAP) Drugs Sales and Market Share by Manufacturer (2018-2019)
3.2 Global Hospital-acquired Pneumonia (HAP) Drugs Revenue and Market Share by Manufacturer (2018-2019)
3.3 Market Concentration Rate
3.3.1 Top 3 Hospital-acquired Pneumonia (HAP) Drugs Manufacturer Market Share in 2019
3.3.2 Top 6 Hospital-acquired Pneumonia (HAP) Drugs Manufacturer Market Share in 2019
3.4 Market Competition Trend
4 Global Market Analysis by Regions
4.1 Global Hospital-acquired Pneumonia (HAP) Drugs Sales, Revenue and Market Share by Regions
4.1.1 Global Hospital-acquired Pneumonia (HAP) Drugs Sales and Market Share by Regions (2015-2020)
4.1.2 Global Hospital-acquired Pneumonia (HAP) Drugs Revenue and Market Share by Regions (2015-2020)
4.2 North America Hospital-acquired Pneumonia (HAP) Drugs Sales and Growth Rate (2015-2020)
4.3 Europe Hospital-acquired Pneumonia (HAP) Drugs Sales and Growth Rate (2015-2020)
4.4 Asia-Pacific Hospital-acquired Pneumonia (HAP) Drugs Sales and Growth Rate (2015-2020)
4.5 South America Hospital-acquired Pneumonia (HAP) Drugs Sales and Growth Rate (2015-2020)
4.6 Middle East and Africa Hospital-acquired Pneumonia (HAP) Drugs Sales and Growth Rate (2015-2020)
5 North America by Country
5.1 North America Hospital-acquired Pneumonia (HAP) Drugs Sales, Revenue and Market Share by Country
5.1.1 North America Hospital-acquired Pneumonia (HAP) Drugs Sales and Market Share by Country (2015-2020)
5.1.2 North America Hospital-acquired Pneumonia (HAP) Drugs Revenue and Market Share by Country (2015-2020)
5.2 United States Hospital-acquired Pneumonia (HAP) Drugs Sales and Growth Rate (2015-2020)
5.3 Canada Hospital-acquired Pneumonia (HAP) Drugs Sales and Growth Rate (2015-2020)
5.4 Mexico Hospital-acquired Pneumonia (HAP) Drugs Sales and Growth Rate (2015-2020)
6 Europe by Country
6.1 Europe Hospital-acquired Pneumonia (HAP) Drugs Sales, Revenue and Market Share by Country
6.1.1 Europe Hospital-acquired Pneumonia (HAP) Drugs Sales and Market Share by Country (2015-2020)
6.1.2 Europe Hospital-acquired Pneumonia (HAP) Drugs Revenue and Market Share by Country (2015-2020)
6.2 Germany Hospital-acquired Pneumonia (HAP) Drugs Sales and Growth Rate (2015-2020)
6.3 UK Hospital-acquired Pneumonia (HAP) Drugs Sales and Growth Rate (2015-2020)
6.4 France Hospital-acquired Pneumonia (HAP) Drugs Sales and Growth Rate (2015-2020)
6.5 Russia Hospital-acquired Pneumonia (HAP) Drugs Sales and Growth Rate (2015-2020)
6.6 Italy Hospital-acquired Pneumonia (HAP) Drugs Sales and Growth Rate (2015-2020)
7 Asia-Pacific by Regions
7.1 Asia-Pacific Hospital-acquired Pneumonia (HAP) Drugs Sales, Revenue and Market Share by Regions
7.1.1 Asia-Pacific Hospital-acquired Pneumonia (HAP) Drugs Sales and Market Share by Regions (2015-2020)
7.1.2 Asia-Pacific Hospital-acquired Pneumonia (HAP) Drugs Revenue and Market Share by Regions (2015-2020)
7.2 China Hospital-acquired Pneumonia (HAP) Drugs Sales and Growth Rate (2015-2020)
7.3 Japan Hospital-acquired Pneumonia (HAP) Drugs Sales and Growth Rate (2015-2020)
7.4 Korea Hospital-acquired Pneumonia (HAP) Drugs Sales and Growth Rate (2015-2020)
7.5 India Hospital-acquired Pneumonia (HAP) Drugs Sales and Growth Rate (2015-2020)
7.6 Southeast Asia Hospital-acquired Pneumonia (HAP) Drugs Sales and Growth Rate (2015-2020)
7.7 Australia Hospital-acquired Pneumonia (HAP) Drugs Sales and Growth Rate (2015-2020)
8 South America by Country
8.1 South America Hospital-acquired Pneumonia (HAP) Drugs Sales, Revenue and Market Share by Country
8.1.1 South America Hospital-acquired Pneumonia (HAP) Drugs Sales and Market Share by Country (2015-2020)
8.1.2 South America Hospital-acquired Pneumonia (HAP) Drugs Revenue and Market Share by Country (2015-2020)
8.2 Brazil Hospital-acquired Pneumonia (HAP) Drugs Sales and Growth Rate (2015-2020)
8.3 Argentina Hospital-acquired Pneumonia (HAP) Drugs Sales and Growth Rate (2015-2020)
9 Middle East & Africa by Countries
9.1 Middle East & Africa Hospital-acquired Pneumonia (HAP) Drugs Sales, Revenue and Market Share by Country
9.1.1 Middle East & Africa Hospital-acquired Pneumonia (HAP) Drugs Sales and Market Share by Country (2015-2020)
9.1.2 Middle East & Africa Hospital-acquired Pneumonia (HAP) Drugs Revenue and Market Share by Country (2015-2020)
9.2 Saudi Arabia Hospital-acquired Pneumonia (HAP) Drugs Sales and Growth Rate (2015-2020)
9.3 Turkey Hospital-acquired Pneumonia (HAP) Drugs Sales and Growth Rate (2015-2020)
9.4 Egypt Hospital-acquired Pneumonia (HAP) Drugs Sales and Growth Rate (2015-2020)
9.5 South Africa Hospital-acquired Pneumonia (HAP) Drugs Sales and Growth Rate (2015-2020)
10 Market Segment by Type
10.1 Global Hospital-acquired Pneumonia (HAP) Drugs Sales and Market Share by Type (2015-2020)
10.2 Global Hospital-acquired Pneumonia (HAP) Drugs Revenue and Market Share by Type (2015-2020)
10.3 Global Hospital-acquired Pneumonia (HAP) Drugs Price by Type (2015-2020)
11 Global Hospital-acquired Pneumonia (HAP) Drugs Market Segment by Application
11.1 Global Hospital-acquired Pneumonia (HAP) Drugs Sales Market Share by Application (2015-2020)
11.2 Global Hospital-acquired Pneumonia (HAP) Drugs Revenue Market Share by Application (2015-2020)
11.3 Global Hospital-acquired Pneumonia (HAP) Drugs Price by Application (2015-2020)
12 Market Forecast
12.1 Global Hospital-acquired Pneumonia (HAP) Drugs Sales, Revenue and Growth Rate (2021-2025)
12.2 Hospital-acquired Pneumonia (HAP) Drugs Market Forecast by Regions (2021-2025)
12.2.1 North America Hospital-acquired Pneumonia (HAP) Drugs Market Forecast (2021-2025)
12.2.2 Europe Hospital-acquired Pneumonia (HAP) Drugs Market Forecast (2021-2025)
12.2.3 Asia-Pacific Hospital-acquired Pneumonia (HAP) Drugs Market Forecast (2021-2025)
12.2.4 South America Hospital-acquired Pneumonia (HAP) Drugs Market Forecast (2021-2025)
12.2.5 Middle East & Africa Hospital-acquired Pneumonia (HAP) Drugs Market Forecast (2021-2025)
12.3 Hospital-acquired Pneumonia (HAP) Drugs Market Forecast by Type (2021-2025)
12.3.1 Global Hospital-acquired Pneumonia (HAP) Drugs Sales Forecast by Type (2021-2025)
12.3.2 Global Hospital-acquired Pneumonia (HAP) Drugs Market Share Forecast by Type (2021-2025)
12.4 Hospital-acquired Pneumonia (HAP) Drugs Market Forecast by Application (2021-2025)
12.4.1 Global Hospital-acquired Pneumonia (HAP) Drugs Sales Forecast by Application (2021-2025)
12.4.2 Global Hospital-acquired Pneumonia (HAP) Drugs Market Share Forecast by Application (2021-2025)
13 Sales Channel, Distributors, Traders and Dealers
13.1 Sales Channel
13.1.1 Direct Marketing
13.1.2 Indirect Marketing
13.2 Distributors, Traders and Dealers
14 Research Findings and Conclusion
15 Appendix
15.1 Methodology
15.2 Data Source
15.3 Disclaimer
15.4 About US
Table 1. Global Hospital-acquired Pneumonia (HAP) Drugs Revenue (USD Million) by Type: 2015 VS 2019 VS 2025
Table 2. Breakdown of Hospital-acquired Pneumonia (HAP) Drugs by Company Type (Tier 1, Tier 2 and Tier 3)
Table 3. Global Hospital-acquired Pneumonia (HAP) Drugs Revenue (USD Million) by Application: 2015 VS 2019 VS 2025
Table 4. Market Opportunities in Next Few Years
Table 5. Market Risks Analysis
Table 6. Market Drivers
Table 7. Pfizer Basic Information, Manufacturing Base and Competitors
Table 8. Pfizer Hospital-acquired Pneumonia (HAP) Drugs Major Business
Table 9. Pfizer Hospital-acquired Pneumonia (HAP) Drugs Total Revenue (USD Million) (2017-2018)
Table 10. Pfizer SWOT Analysis
Table 11. Pfizer Hospital-acquired Pneumonia (HAP) Drugs Product and Services
Table 12. Pfizer Hospital-acquired Pneumonia (HAP) Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 13. Arsanis Basic Information, Manufacturing Base and Competitors
Table 14. Arsanis Hospital-acquired Pneumonia (HAP) Drugs Major Business
Table 15. Arsanis Hospital-acquired Pneumonia (HAP) Drugs Total Revenue (USD Million) (2017-2018)
Table 16. Arsanis SWOT Analysis
Table 17. Arsanis Hospital-acquired Pneumonia (HAP) Drugs Product and Services
Table 18. Arsanis Hospital-acquired Pneumonia (HAP) Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 19. Mylan Basic Information, Manufacturing Base and Competitors
Table 20. Mylan Hospital-acquired Pneumonia (HAP) Drugs Major Business
Table 21. Mylan Hospital-acquired Pneumonia (HAP) Drugs Total Revenue (USD Million) (2017-2018)
Table 22. Mylan SWOT Analysis
Table 23. Mylan Hospital-acquired Pneumonia (HAP) Drugs Product and Services
Table 24. Mylan Hospital-acquired Pneumonia (HAP) Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 25. GlaxoSmithKline Basic Information, Manufacturing Base and Competitors
Table 26. GlaxoSmithKline Hospital-acquired Pneumonia (HAP) Drugs Major Business
Table 27. GlaxoSmithKline Hospital-acquired Pneumonia (HAP) Drugs Total Revenue (USD Million) (2017-2018)
Table 28. GlaxoSmithKline SWOT Analysis
Table 29. GlaxoSmithKline Hospital-acquired Pneumonia (HAP) Drugs Product and Services
Table 30. GlaxoSmithKline Hospital-acquired Pneumonia (HAP) Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 31. AstraZeneca Basic Information, Manufacturing Base and Competitors
Table 32. AstraZeneca Hospital-acquired Pneumonia (HAP) Drugs Major Business
Table 33. AstraZeneca Hospital-acquired Pneumonia (HAP) Drugs Total Revenue (USD Million) (2017-2018)
Table 34. AstraZeneca SWOT Analysis
Table 35. AstraZeneca Hospital-acquired Pneumonia (HAP) Drugs Product and Services
Table 36. AstraZeneca Hospital-acquired Pneumonia (HAP) Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 37. Merck Basic Information, Manufacturing Base and Competitors
Table 38. Merck Hospital-acquired Pneumonia (HAP) Drugs Major Business
Table 39. Merck Hospital-acquired Pneumonia (HAP) Drugs Total Revenue (USD Million) (2017-2018)
Table 40. Merck SWOT Analysis
Table 41. Merck Hospital-acquired Pneumonia (HAP) Drugs Product and Services
Table 42. Merck Hospital-acquired Pneumonia (HAP) Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 43. Shinogi Basic Information, Manufacturing Base and Competitors
Table 44. Shinogi Hospital-acquired Pneumonia (HAP) Drugs Major Business
Table 45. Shinogi Hospital-acquired Pneumonia (HAP) Drugs Total Revenue (USD Million) (2017-2018)
Table 46. Shinogi SWOT Analysis
Table 47. Shinogi Hospital-acquired Pneumonia (HAP) Drugs Product and Services
Table 48. Shinogi Hospital-acquired Pneumonia (HAP) Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 49. Teva Pharmaceutical Industries Basic Information, Manufacturing Base and Competitors
Table 50. Teva Pharmaceutical Industries Hospital-acquired Pneumonia (HAP) Drugs Major Business
Table 51. Teva Pharmaceutical Industries Hospital-acquired Pneumonia (HAP) Drugs Total Revenue (USD Million) (2017-2018)
Table 52. Teva Pharmaceutical Industries SWOT Analysis
Table 53. Teva Pharmaceutical Industries Hospital-acquired Pneumonia (HAP) Drugs Product and Services
Table 54. Teva Pharmaceutical Industries Hospital-acquired Pneumonia (HAP) Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 55. Novartis Basic Information, Manufacturing Base and Competitors
Table 56. Novartis Hospital-acquired Pneumonia (HAP) Drugs Major Business
Table 57. Novartis Hospital-acquired Pneumonia (HAP) Drugs Total Revenue (USD Million) (2017-2018)
Table 58. Novartis SWOT Analysis
Table 59. Novartis Hospital-acquired Pneumonia (HAP) Drugs Product and Services
Table 60. Novartis Hospital-acquired Pneumonia (HAP) Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 61. Combioxin Basic Information, Manufacturing Base and Competitors
Table 62. Combioxin Hospital-acquired Pneumonia (HAP) Drugs Major Business
Table 63. Combioxin Hospital-acquired Pneumonia (HAP) Drugs Total Revenue (USD Million) (2017-2018)
Table 64. Combioxin SWOT Analysis
Table 65. Combioxin Hospital-acquired Pneumonia (HAP) Drugs Product and Services
Table 66. Combioxin Hospital-acquired Pneumonia (HAP) Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 67. Sun Pharmaceutical Industries Basic Information, Manufacturing Base and Competitors
Table 68. Sun Pharmaceutical Industries Hospital-acquired Pneumonia (HAP) Drugs Major Business
Table 69. Sun Pharmaceutical Industries Hospital-acquired Pneumonia (HAP) Drugs Total Revenue (USD Million) (2017-2018)
Table 70. Sun Pharmaceutical Industries SWOT Analysis
Table 71. Sun Pharmaceutical Industries Hospital-acquired Pneumonia (HAP) Drugs Product and Services
Table 72. Sun Pharmaceutical Industries Hospital-acquired Pneumonia (HAP) Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 73. The Medicines Company Basic Information, Manufacturing Base and Competitors
Table 74. The Medicines Company Hospital-acquired Pneumonia (HAP) Drugs Major Business
Table 75. The Medicines Company Hospital-acquired Pneumonia (HAP) Drugs Total Revenue (USD Million) (2017-2018)
Table 76. The Medicines Company SWOT Analysis
Table 77. The Medicines Company Hospital-acquired Pneumonia (HAP) Drugs Product and Services
Table 78. The Medicines Company Hospital-acquired Pneumonia (HAP) Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 79. Theravance Biopharma Basic Information, Manufacturing Base and Competitors
Table 80. Theravance Biopharma Hospital-acquired Pneumonia (HAP) Drugs Major Business
Table 81. Theravance Biopharma Hospital-acquired Pneumonia (HAP) Drugs Total Revenue (USD Million) (2017-2018)
Table 82. Theravance Biopharma SWOT Analysis
Table 83. Theravance Biopharma Hospital-acquired Pneumonia (HAP) Drugs Product and Services
Table 84. Theravance Biopharma Hospital-acquired Pneumonia (HAP) Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 85. Global Hospital-acquired Pneumonia (HAP) Drugs Sales by Manufacturer (2018-2019) (K Pcs)
Table 86. Global Hospital-acquired Pneumonia (HAP) Drugs Revenue by Manufacturer (2018-2019) (USD Million)
Table 87. Global Hospital-acquired Pneumonia (HAP) Drugs Sales by Regions (2015-2020) (K Pcs)
Table 88. Global Hospital-acquired Pneumonia (HAP) Drugs Sales Market Share by Regions (2015-2020)
Table 89. Global Hospital-acquired Pneumonia (HAP) Drugs Revenue by Regions (2015-2020) (USD Million)
Table 90. North America Hospital-acquired Pneumonia (HAP) Drugs Sales by Countries (2015-2020) (K Pcs)
Table 91. North America Hospital-acquired Pneumonia (HAP) Drugs Sales Market Share by Countries (2015-2020)
Table 92. North America Hospital-acquired Pneumonia (HAP) Drugs Revenue by Countries (2015-2020) (USD Million)
Table 93. North America Hospital-acquired Pneumonia (HAP) Drugs Revenue Market Share by Countries (2015-2020)
Table 94. Europe Hospital-acquired Pneumonia (HAP) Drugs Sales by Countries (2015-2020) (K Pcs)
Table 95. Europe Hospital-acquired Pneumonia (HAP) Drugs Sales Market Share by Countries (2015-2020)
Table 96. Europe Hospital-acquired Pneumonia (HAP) Drugs Revenue by Countries (2015-2020) (USD Million)
Table 97. Asia-Pacific Hospital-acquired Pneumonia (HAP) Drugs Sales by Regions (2015-2020) (K Pcs)
Table 98. Asia-Pacific Hospital-acquired Pneumonia (HAP) Drugs Sales Market Share by Regions (2015-2020)
Table 99. Asia-Pacific Hospital-acquired Pneumonia (HAP) Drugs Revenue by Regions (2015-2020) (USD Million)
Table 100. South America Hospital-acquired Pneumonia (HAP) Drugs Sales by Countries (2015-2020) (K Pcs)
Table 101. South America Hospital-acquired Pneumonia (HAP) Drugs Sales Market Share by Countries (2015-2020)
Table 102. South America Hospital-acquired Pneumonia (HAP) Drugs Revenue by Countries (2015-2020) (USD Million)
Table 103. South America Hospital-acquired Pneumonia (HAP) Drugs Revenue Market Share by Countries (2015-2020)
Table 104. Middle East & Africa Hospital-acquired Pneumonia (HAP) Drugs Sales by Countries (2015-2020) (K Pcs)
Table 105. Middle East & Africa Hospital-acquired Pneumonia (HAP) Drugs Sales Market Share by Countries (2015-2020)
Table 106. Middle East & Africa Hospital-acquired Pneumonia (HAP) Drugs Revenue by Countries (2015-2020) (USD Million)
Table 107. Middle East & Africa Hospital-acquired Pneumonia (HAP) Drugs Revenue Market Share by Countries (2015-2020)
Table 108. Global Hospital-acquired Pneumonia (HAP) Drugs Sales by Type (2015-2020) (K Pcs)
Table 109. Global Hospital-acquired Pneumonia (HAP) Drugs Sales Share by Type (2015-2020)
Table 110. Global Hospital-acquired Pneumonia (HAP) Drugs Revenue by Type (2015-2020) (USD Million)
Table 111. Global Hospital-acquired Pneumonia (HAP) Drugs Revenue Share by Type (2015-2020)
Table 112. Global Hospital-acquired Pneumonia (HAP) Drugs Sales by Application (2015-2020) (K Pcs)
Table 113. Global Hospital-acquired Pneumonia (HAP) Drugs Sales Share by Application (2015-2020)
Table 114. Global Hospital-acquired Pneumonia (HAP) Drugs Sales Forecast by Regions (2021-2025) (K Pcs)
Table 115. Global Hospital-acquired Pneumonia (HAP) Drugs Market Share Forecast by Regions (2021-2025)
Table 116. Global Hospital-acquired Pneumonia (HAP) Drugs Sales Forecast by Type (2021-2025) (K Pcs)
Table 117. Global Hospital-acquired Pneumonia (HAP) Drugs Market Share Forecast by Type (2021-2025)
Table 118. Global Hospital-acquired Pneumonia (HAP) Drugs Sales Forecast by Application (2021-2025)
Table 119. Global Hospital-acquired Pneumonia (HAP) Drugs Market Share Forecast by Application (2021-2025)
Table 120. Direct Channel Pros & Cons
Table 121. Indirect Channel Pros & Cons
Table 122. Distributors/Traders/ Dealers List
List of Figures
Figure 1. Hospital-acquired Pneumonia (HAP) Drugs Picture
Figure 2. Global Sales Market Share of Hospital-acquired Pneumonia (HAP) Drugs by Type in 2019
Figure 3. Antibacterial Picture
Figure 4. Antiviral Picture
Figure 5. Antifungal Picture
Figure 6. Hospital-acquired Pneumonia (HAP) Drugs Sales Market Share by Application in 2018
Figure 7. Hospitals Picture
Figure 8. Clinics Picture
Figure 9. Other Picture
Figure 10. Global Hospital-acquired Pneumonia (HAP) Drugs Market Status and Outlook (2015-2025) (USD Million)
Figure 11. United States Hospital-acquired Pneumonia (HAP) Drugs Revenue (Value) and Growth Rate (2015-2025)
Figure 12. Canada Hospital-acquired Pneumonia (HAP) Drugs Revenue (Value) and Growth Rate (2015-2025)
Figure 13. Mexico Hospital-acquired Pneumonia (HAP) Drugs Revenue (Value) and Growth Rate (2015-2025)
Figure 14. Germany Hospital-acquired Pneumonia (HAP) Drugs Revenue (Value) and Growth Rate (2015-2025)
Figure 15. France Hospital-acquired Pneumonia (HAP) Drugs Revenue (Value) and Growth Rate (2015-2025)
Figure 16. UK Hospital-acquired Pneumonia (HAP) Drugs Revenue (Value) and Growth Rate (2015-2025)
Figure 17. Russia Hospital-acquired Pneumonia (HAP) Drugs Revenue (Value) and Growth Rate (2015-2025)
Figure 18. Italy Hospital-acquired Pneumonia (HAP) Drugs Revenue (Value) and Growth Rate (2015-2025)
Figure 19. China Hospital-acquired Pneumonia (HAP) Drugs Revenue (Value) and Growth Rate (2015-2025)
Figure 20. Japan Hospital-acquired Pneumonia (HAP) Drugs Revenue (Value) and Growth Rate (2015-2025)
Figure 21. Korea Hospital-acquired Pneumonia (HAP) Drugs Revenue (Value) and Growth Rate (2015-2025)
Figure 22. India Hospital-acquired Pneumonia (HAP) Drugs Revenue (Value) and Growth Rate (2015-2025)
Figure 23. Southeast Asia Hospital-acquired Pneumonia (HAP) Drugs Revenue (Value) and Growth Rate (2015-2025)
Figure 24. Australia Hospital-acquired Pneumonia (HAP) Drugs Revenue (Value) and Growth Rate (2015-2025) (USD Million)
Figure 25. Brazil Hospital-acquired Pneumonia (HAP) Drugs Revenue (Value) and Growth Rate (2015-2025)
Figure 26. Egypt Hospital-acquired Pneumonia (HAP) Drugs Revenue (Value) and Growth Rate (2015-2025)
Figure 27. Saudi Arabia Hospital-acquired Pneumonia (HAP) Drugs Revenue (Value) and Growth Rate (2015-2025)
Figure 28. South Africa Hospital-acquired Pneumonia (HAP) Drugs Revenue (Value) and Growth Rate (2015-2025)
Figure 29. Turkey Hospital-acquired Pneumonia (HAP) Drugs Revenue (Value) and Growth Rate (2015-2025)
Figure 30. Global Hospital-acquired Pneumonia (HAP) Drugs Sales Market Share by Manufacturer in 2019
Figure 31. Global Hospital-acquired Pneumonia (HAP) Drugs Revenue Market Share by Manufacturer in 2019
Figure 32. Top 3 Hospital-acquired Pneumonia (HAP) Drugs Manufacturer (Revenue) Market Share in 2019
Figure 33. Top 6 Hospital-acquired Pneumonia (HAP) Drugs Manufacturer (Revenue) Market Share in 2019
Figure 34. Key Manufacturer Market Share Trend
Figure 35. Global Hospital-acquired Pneumonia (HAP) Drugs Sales and Growth Rate (2015-2020) (K Pcs)
Figure 36. Global Hospital-acquired Pneumonia (HAP) Drugs Revenue and Growth Rate (2015-2020) (USD Million)
Figure 37. Global Hospital-acquired Pneumonia (HAP) Drugs Revenue Market Share by Regions (2015-2020)
Figure 38. Global Hospital-acquired Pneumonia (HAP) Drugs Revenue Market Share by Regions in 2018
Figure 39. North America Hospital-acquired Pneumonia (HAP) Drugs Sales and Growth Rate (2015-2020)
Figure 40. Europe Hospital-acquired Pneumonia (HAP) Drugs Sales and Growth Rate (2015-2020)
Figure 41. Asia-Pacific Hospital-acquired Pneumonia (HAP) Drugs Sales and Growth Rate (2015-2020)
Figure 42. South America Hospital-acquired Pneumonia (HAP) Drugs Sales and Growth Rate (2015-2020)
Figure 43. Middle East & Africa Hospital-acquired Pneumonia (HAP) Drugs Sales and Growth Rate (2015-2020)
Figure 44. North America Hospital-acquired Pneumonia (HAP) Drugs Revenue and Growth Rate (2015-2020) (USD Million)
Figure 45. North America Hospital-acquired Pneumonia (HAP) Drugs Sales Market Share by Countries (2015-2020)
Figure 46. North America Hospital-acquired Pneumonia (HAP) Drugs Sales Market Share by Countries in 2018
Figure 47. North America Hospital-acquired Pneumonia (HAP) Drugs Revenue Market Share by Countries (2015-2020) (USD Million)
Figure 48. North America Hospital-acquired Pneumonia (HAP) Drugs Revenue Market Share by Countries in 2018
Figure 49. United States Hospital-acquired Pneumonia (HAP) Drugs Sales and Growth Rate (2015-2020) (K Pcs)
Figure 50. Canada Hospital-acquired Pneumonia (HAP) Drugs Sales and Growth Rate (2015-2020) (K Pcs)
Figure 51. Mexico Hospital-acquired Pneumonia (HAP) Drugs Sales and Growth Rate (2015-2020) (K Pcs)
Figure 52. Europe Hospital-acquired Pneumonia (HAP) Drugs Revenue and Growth Rate (2015-2020) (USD Million)
Figure 53. Europe Hospital-acquired Pneumonia (HAP) Drugs Revenue Market Share by Countries (2015-2020)
Figure 54. Europe Hospital-acquired Pneumonia (HAP) Drugs Revenue Market Share by Countries in 2019
Figure 55. Germany Hospital-acquired Pneumonia (HAP) Drugs Sales and Growth Rate (2015-2020) (K Pcs)
Figure 56. UK Hospital-acquired Pneumonia (HAP) Drugs Sales and Growth Rate (2015-2020) (K Pcs)
Figure 57. France Hospital-acquired Pneumonia (HAP) Drugs Sales and Growth Rate (2015-2020) (K Pcs)
Figure 58. Russia Hospital-acquired Pneumonia (HAP) Drugs Sales and Growth Rate (2015-2020) (K Pcs)
Figure 59. Italy Hospital-acquired Pneumonia (HAP) Drugs Sales and Growth Rate (2015-2020) (K Pcs)
Figure 60. Asia-Pacific Hospital-acquired Pneumonia (HAP) Drugs Revenue and Growth Rate (2015-2020) (USD Million)
Figure 61. Asia-Pacific Hospital-acquired Pneumonia (HAP) Drugs Sales Market Share by Regions 2019
Figure 62. Asia-Pacific Hospital-acquired Pneumonia (HAP) Drugs Revenue Market Share by Regions 2019
Figure 63. China Hospital-acquired Pneumonia (HAP) Drugs Sales and Growth Rate (2015-2020) (K Pcs)
Figure 64. Japan Hospital-acquired Pneumonia (HAP) Drugs Sales and Growth Rate (2015-2020) (K Pcs)
Figure 65. Korea Hospital-acquired Pneumonia (HAP) Drugs Sales and Growth Rate (2015-2020) (K Pcs)
Figure 66. India Hospital-acquired Pneumonia (HAP) Drugs Sales and Growth Rate (2015-2020) (K Pcs)
Figure 67. Southeast Asia Hospital-acquired Pneumonia (HAP) Drugs Sales and Growth Rate (2015-2020) (K Pcs)
Figure 68. South America Hospital-acquired Pneumonia (HAP) Drugs Revenue and Growth Rate (2015-2020) (USD Million)
Figure 69. South America Hospital-acquired Pneumonia (HAP) Drugs Sales Market Share by Countries in 2019
Figure 70. South America Hospital-acquired Pneumonia (HAP) Drugs Revenue Market Share by Countries in 2019
Figure 71. Brazil Hospital-acquired Pneumonia (HAP) Drugs Sales and Growth Rate (2015-2020) (K Pcs)
Figure 72. Argentina Hospital-acquired Pneumonia (HAP) Drugs Sales and Growth Rate (2015-2020) (K Pcs)
Figure 73. Middle East and Africa Hospital-acquired Pneumonia (HAP) Drugs Revenue and Growth Rate (2015-2020) (USD Million)
Figure 74. Middle East and Africa Hospital-acquired Pneumonia (HAP) Drugs Sales Market Share by Countries in 2019
Figure 75. Middle East and Africa Hospital-acquired Pneumonia (HAP) Drugs Revenue Market Share by Countries (2015-2020)
Figure 76. Middle East and Africa Hospital-acquired Pneumonia (HAP) Drugs Revenue Market Share by Countries in 2019
Figure 77. Saudi Arabia Hospital-acquired Pneumonia (HAP) Drugs Sales and Growth Rate (2015-2020) (K Pcs)
Figure 78. Egypt Hospital-acquired Pneumonia (HAP) Drugs Sales and Growth Rate (2015-2020) (K Pcs)
Figure 79. Turkey Hospital-acquired Pneumonia (HAP) Drugs Sales and Growth Rate (2015-2020) (K Pcs)
Figure 80. South Africa Hospital-acquired Pneumonia (HAP) Drugs Sales and Growth Rate (2015-2020) (K Pcs)
Figure 81. Global Hospital-acquired Pneumonia (HAP) Drugs Sales and Growth Rate (2021-2025) (K Pcs)
Figure 82. Global Hospital-acquired Pneumonia (HAP) Drugs Revenue and Growth Rate (2021-2025) (USD Million)
Figure 83. North America Sales Hospital-acquired Pneumonia (HAP) Drugs Market Forecast (2021-2025) (K Pcs)
Figure 84. Europe Sales Hospital-acquired Pneumonia (HAP) Drugs Market Forecast (2021-2025) (K Pcs)
Figure 85. Asia-Pacific Sales Hospital-acquired Pneumonia (HAP) Drugs Market Forecast (2021-2025) (K Pcs)
Figure 86. South America Sales Hospital-acquired Pneumonia (HAP) Drugs Market Forecast (2021-2025) (K Pcs)
Figure 87. Middle East & Africa Sales Hospital-acquired Pneumonia (HAP) Drugs Market Forecast (2021-2025) (K Pcs)
Figure 88. Sales Channel: Direct Channel vs Indirect Channel
院内肺炎（HAP）治療薬の世界市場（～2026年） HAP is a type of pneumonia that is caused after 48 hours of hospitalization. HAP is one of the major challenges faced by the public healthcare system today. The disease is the second most common type of hospital-acquired infections. Pneumonia is an inflammatory condition of lungs and mainly affects …- 院内肺炎予防の世界市場（～2026年） HAP is defined as a lower respiratory infection, which does not incubate at the time of hospital admission but presents clinically 2 or more days after hospitalization.Incidence of HAP is more prevalent in the medical and surgical Intensive Care Units, and results in additional cost to the healthcar…
- 院内肺炎治療薬の世界市場（～2026年） Hospital-acquired pneumonia (HAP) or nosocomial pneumonia refers to any pneumonia contracted by a patient in a hospital at least 48–72 hours after being admitted. It is thus distinguished from community-acquired pneumonia. It is usually caused by a bacterial infection, rather than a virus. Market An…
- 市中肺炎（CAP）の世界市場（～2026年） Community-acquired pneumonia (CAP) refers to pneumonia (any of several lung diseases) contracted by a person with little contact with the healthcare system. The market of CAP treatment and diagnosis in further segmented with respect to major geographies of North America, Europe, Asia-Pacific, and La…
- 医療関連感染（HAI）診断の世界市場（～2026年） Patients may catch infections during they are in the hospital, the hospital acquired infection test is used to diagnose those infections. The industry is anticipated to witness a significant growth in the next few years. One of the key factors driving industry growth is the rising geriatric populati…